多菌种益生菌辅助治疗种植体周围黏膜炎的随机对照试验
本随机安慰剂对照试验纳入36例无牙颌种植体周围黏膜炎患者,评估含鼠李糖乳杆菌HN001、副干酪乳杆菌Lpc-37和动物双歧杆菌乳亚种HN019的多菌种益生菌辅助机械清创的效果。结果显示试验组24周时种植体周围健康恢复率高于对照组(72.2% vs 33.3%),探诊出血在12周和24周均低于对照组。
要点
- 多菌种益生菌局部加全身辅助机械清创可提高种植体周围健康恢复率。
- 24周时试验组种植体周围健康恢复率为72.2%,对照组为33.3%。
- 两组改良菌斑指数和探诊深度无显著差异。
核心结论
- 含鼠李糖乳杆菌HN001、副干酪乳杆菌Lpc-37和动物双歧杆菌乳亚种HN019的多菌种益生菌(局部和全身给药)辅助重复机械清创,在无牙颌患者种植体周围黏膜炎治疗中带来额外临床和免疫学益处。
研究设计与样本
- 随机安慰剂对照临床试验,纳入36例种植体周围黏膜炎患者,随机分为试验组(益生菌)和对照组(安慰剂),每组18例。
- 所有种植体周围黏膜炎位点在基线和12周接受机械清创并局部涂抹凝胶(益生菌或安慰剂),初始机械清创后患者每日两次服用益生菌或安慰剂胶囊共12周。
- 在基线、12周和24周收集临床指标(改良龈沟出血指数、改良菌斑指数、探诊深度、探诊出血)和免疫学指标,数据统计学分析(p < .05)。
主要发现
- 24周时试验组种植体周围健康恢复病例的患病率高于对照组(72.2% vs 33.3%,p < .05)。
- 试验组(n = 18)与对照组(n = 18)之间改良菌斑指数和探诊深度无显著差异。
- 24周时试验组改良龈沟出血指数0分百分比高于对照组(p < .05)。
- 与基线相比,两组在12周和24周探诊出血均降低(p < .05);试验组探诊出血在12周(平均差 = -14.54%;95%CI = -28.87至0.22;p = .0163)和24周(平均差 = -12.56%;95%CI = -26.51至1.37;p = .0090)低于对照组。
- 24周时仅试验组白细胞介素-1β、白细胞介素-6、白细胞介素-8和肿瘤坏死因子-α水平低于基线(p < .05)。
临床怎么用
- 原文结论认为多菌种益生菌局部和全身辅助重复机械清创在无牙颌患者种植体周围黏膜炎治疗中带来额外临床和免疫学益处。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: This randomized placebo-controlled clinical trial evaluated the effects of multispecies probiotic containing Lactobacillus rhamnosus HN001™, Lactobacillus paracasei Lpc-37®, and Bifidobacterium animalis subsp lactis HN019™ as an adjunct to mechanical debridement (MD) on changes in bleeding on probing (BOP) in edentulous patients with peri-implant mucositis (PiM). MATERIALS AND METHODS: Patients were randomly assigned to test (probiotic) or control (placebo) groups. All sites with PiM received MD and topical gel application (probiotic or placebo) at baseline and 12 weeks. After initial MD, patients consumed probiotic or placebo capsules twice a day for 12 weeks. Clinical (modified sulcus bleeding index [mSBI]; modified plaque index [mPI]; probing depth [PD]; and BOP) and immunological parameters were collected at baseline and after 12 and 24 weeks. Data were statistically analysed (p < .05). RESULTS: Thirty-six patients with PiM were recruited. The test group presented higher prevalence (p < .05) of cases of restored peri-implant health at 24 weeks than did the control group (72.2% and 33.3%, respectively). No significant difference was observed between test (n = 18) and control (n = 18) groups for mPI and PD. mSBI %-score 0 was higher in the test group than in the control group at 24 weeks (p < .05). When compared with baseline, both groups presented reduced BOP at 12 and 24 weeks (p < .05). BOP was lower in the test group than in the control group at 12 (mean difference = -14.54%; 95% confidence interval [CI] = -28.87 to 0.22; p = .0163) and 24 (mean difference = -12.56%; 95% CI = -26.51 to 1.37; p = .0090) weeks. At 24 weeks, only the test group presented lower levels of interleukin (IL)-1β, IL-6, IL-8, and tumour necrosis factor (TNF)-α than those at baseline (p < .05). CONCLUSIONS: The multispecies probiotic (administered locally and systemically) containing L. rhamnosus HN001™, L. paracasei Lpc-37®, and B. lactis HN019™ as an adjunct to repeated MD promotes additional clinical and immunological benefits in the treatment of PiM in edentulous patients (ClinicalTrials.gov NCT04187222).
引用
- Santana SI, Silva PHF, Salvador SL, et al. Adjuvant use of multispecies probiotic in the treatment of peri-implant mucositis: A randomized controlled trial. J Clin Periodontol. 2022. PMID: 35634695. doi:10.1111/jcpe.13663
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。